

**GALILEO LIFE SCIENCES INC, also known as MODERN MOBILITY AIDS, INC. SIGNS  
DEFINITIVE AGREEMENT TO ACQUIRE 2542153 ONTARIO INC**

***Acquisition To Expand the Company's Roster of Physicians and Specialists for Its Telehealth  
Services***

Toronto, ONT., November 2, 2022. Galileo Life Sciences, Inc. (OTC: MDRM) (the "Company") is pleased to announce the execution of a Definitive Agreement to acquire all of the common stock of 2542153 ONTARIO INC ("254") in a share exchange agreement.

The closing of this transaction is subject to various conditions including but not limited to the satisfactory completion of due diligence within 60 days. For more information pertaining to the specifics of the Definitive Agreement including the structure of the acquisition, please see the Company's most recent filing with OTCIQ.

2542143 Ontario Inc, is an Ontario company that provides physician and specialist services for Virtual Care Clinics. 254 has amassed a roster of physicians and specialists who have over 30 years of experience collectively in providing virtual care.

In addition, 254 has been supplying PPE products to the healthcare industry for 4 years with sales of over one million dollars per year

Tito DiMarco, CEO of Galileo Life Sciences, Inc, stated, "We are extremely pleased to have signed this Definitive Agreement. 245 possesses key attributes that we look for in a company." He also stated, "254 is an established organization with vast experience in providing virtual care services and the knowledge pool will be very useful to Galileo in expanding its business plan globally. Galileo will also continue expanding the PPE business established by 254. I am confident that the combined assets of both companies will greatly enhance our value as a "Comprehensive Health Care Organization"

About Galileo Life Science, Inc.

Modern Mobility Aids, Inc. has recently revamped its corporate infrastructure and now plans to direct its focus and energies on multibillion-dollar Virtual Care services. Through the formation of its new business model, the Company expects to implement an aggressive campaign in order to seek out technologies, medical experts, and opportunities within the healthcare sector. around the globe. The Company is confident that strategic acquisitions and first-stage investments will play a pivotal role in the Company's success in building a successful global entity.

## Safe Harbor

This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) potential acquisitions, (iii) trends affecting its financial condition or results of operations; (iv) growth strategy and operating strategy. The words "may," "would," "will," "expect," "intend," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in the Company's filings with OTCIQ.

Contact: Galileo Life Sciences, Inc.

Tito DiMarco

Email: [tdimarco@mdrminc.com](mailto:tdimarco@mdrminc.com)